Around 1,000 people a year are expected to become eligible for the targeted treatment.
NICE recommends Enhertu for advanced breast cancer
NICE has recommended trastuzumab deruxtecan (Enhertu) for routine NHS use in England for eligible people with HER2-low advanced breast cancer after chemotherapy.